Skip to main content
Erschienen in: Medical Oncology 3/2012

01.09.2012 | Original Paper

Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits

verfasst von: Ren-chun Lai, Xu-dong Wang, Xu Zhang, Wen-qian Lin, Tie-hua Rong

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to investigate the feasibility of using serum heart fatty acid-binding protein (H-FABP) concentrations as an early biomarker for doxorubicin-induced myocardial damage. Forty-four male rabbits were randomly divided into a control (8 rabbits) or one of four doxorubicin groups (8 rabbits in each group). Rabbits in the control group received saline, whereas rabbits in the doxorubicin group received 2 mg/kg doxorubicin weekly for 1–8 weeks. Rabbits in the doxorubicin groups received doxorubicin 2 mg/kg for one (Group 1, 8 rabbits), two (Group 2, 8 rabbits), four (Group 3, 9 rabbits), or eight (Group 4, 11 rabbits) weeks. Echocardiography was performed to measure left ventricular ejection fraction (LVEF), shortening fraction (FS), and E/A ratio. Cardiotoxicity scores were assessed by light microscopy using Billingham’s method and also by electron microscopy. Serum H-FABP concentrations were quantified by a rabbit-specific enzyme-linked immunosorbent assay. Decreased LVEF, FS, and E/A ratio were detected in Group 4 (P < 0.05). Billingham cardiomyopathy scores of the rabbits in Group 3 were significantly higher (P < 0.05) than those of rabbits in the control group or Groups 1 or 2. Billingham cardiomyopathy scores in Group 4 were the highest of all groups (P < 0.05). Myocardial injury was demonstrable by electron microscopy in rabbits in Groups 2, 3, and 4. Compared with the control group, serum H-FABP concentrations increased only in Group 4 (P < 0.05). Serum H-FABP concentrations may not be a sensitive method for assessing early cardiotoxicity of doxorubicin.
Literatur
1.
Zurück zum Zitat Alvarez JA, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr. 2007;19:23–31.PubMedCrossRef Alvarez JA, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr. 2007;19:23–31.PubMedCrossRef
2.
Zurück zum Zitat Du XL, Xia R, Burau K, Liu CC. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncol 2010;22. Du XL, Xia R, Burau K, Liu CC. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncol 2010;22.
3.
4.
Zurück zum Zitat Weidemann F, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26:1221–7.PubMedCrossRef Weidemann F, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26:1221–7.PubMedCrossRef
5.
Zurück zum Zitat Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem. 2006;52:19–29.PubMedCrossRef Azzazy HM, Pelsers MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem. 2006;52:19–29.PubMedCrossRef
6.
Zurück zum Zitat O’Donoghue M, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114:550–7.PubMedCrossRef O’Donoghue M, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114:550–7.PubMedCrossRef
7.
Zurück zum Zitat Li CJ, et al. Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. Acta Pharmacol Sin. 2010;31:307–12.PubMedCrossRef Li CJ, et al. Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. Acta Pharmacol Sin. 2010;31:307–12.PubMedCrossRef
8.
Zurück zum Zitat Haltern G, et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol. 2010;105:1–9.PubMedCrossRef Haltern G, et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol. 2010;105:1–9.PubMedCrossRef
9.
Zurück zum Zitat Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865–72.PubMed Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865–72.PubMed
10.
Zurück zum Zitat Gabrielson K, et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res. 2007;67:1436–41.PubMedCrossRef Gabrielson K, et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res. 2007;67:1436–41.PubMedCrossRef
11.
Zurück zum Zitat Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007;151:771–8.PubMedCrossRef Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007;151:771–8.PubMedCrossRef
12.
Zurück zum Zitat Dudka J, et al. The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig Med Dosw (Online). 2009;63:225–33. Dudka J, et al. The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig Med Dosw (Online). 2009;63:225–33.
13.
Zurück zum Zitat Horacek JM, et al. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol. 2010;32:97–9.PubMed Horacek JM, et al. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol. 2010;32:97–9.PubMed
14.
Zurück zum Zitat Horacek JM, et al. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia. Exp Oncol. 2008;30:157–9.PubMed Horacek JM, et al. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia. Exp Oncol. 2008;30:157–9.PubMed
15.
Zurück zum Zitat Lipshultz SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.PubMedCrossRef Lipshultz SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.PubMedCrossRef
16.
Zurück zum Zitat Steinherz LJ, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics. 1992;89:942–9.PubMed Steinherz LJ, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics. 1992;89:942–9.PubMed
17.
Zurück zum Zitat Van Vleet JF, Ferrans VJ. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res. 1980;41:1462–9.PubMed Van Vleet JF, Ferrans VJ. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res. 1980;41:1462–9.PubMed
Metadaten
Titel
Heart fatty acid-binding protein may not be an early biomarker for anthracycline-induced cardiotoxicity in rabbits
verfasst von
Ren-chun Lai
Xu-dong Wang
Xu Zhang
Wen-qian Lin
Tie-hua Rong
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9843-x

Weitere Artikel der Ausgabe 3/2012

Medical Oncology 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.